Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Sponsor: Gabi Chiorean, MD
Terminated
Terminated due to funding issues.
Other terminated trials from Gabi Chiorean, MD
More terminations from Gabi Chiorean, MD
Other Hepatocellular Carcinoma trials with similar outcome
A PHASE2 clinical study on Hepatocellular Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Gabi Chiorean, MD and has accumulated 7 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Sep 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gabi Chiorean, MD
- OSI Pharmaceuticals
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .